http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 10 Sep 2026 18:40:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Lancet+Publication+Marks+Important+Advance+in+Influenza+Prevention+for+Older+Adults/27049685.html <div class="xn-content"> <p><b>Phase 3 study demonstrates benefits of the first influenza vaccine to combine three proven approaches to enhancing protection for older adults in a single vaccine. </b></p> <p><span class="legendSpanClass"><location value="LU/gb.eng.maiden" idsrc="xmltag.org" >MAIDENHEAD, United Kingdom</location></span>, <span class="legendSpanClass"><chron>Sept. 10, 2026</chron></span> /PRNewswire/ -- <span value="Australia:CSL" idsrc="xmltag.org" >CSL</span> Seqirus, a business of <span value="Australia:CSL" idsrc="xmltag.org">CSL</span> (ASX: <span value="Australia:CSL" idsrc="xmltag.org">CSL</span>; USOTC: CSLLY), today announced publication of pivotal Phase 3 study results for its MF59^®-adjuvanted http://www.streetinsider.com/Press+Releases/Lancet+Publication+Marks+Important+Advance+in+Influenza+Prevention+for+Older+Adults/27049685.html Thu, 10 Sep 2026 18:40:00 -0400 CSLLY http://www.streetinsider.com/PRNewswire/Lancet+Publication+Marks+Important+Advance+in+Influenza+Prevention+for+Older+Adults/27049685.html <div class="xn-content"> <p><b>Phase 3 study demonstrates benefits of the first influenza vaccine to combine three proven approaches to enhancing protection for older adults in a single vaccine. </b></p> <p><span class="legendSpanClass"><location value="LU/gb.eng.maiden" idsrc="xmltag.org" >MAIDENHEAD, United Kingdom</location></span>, <span class="legendSpanClass"><chron>Sept. 10, 2026</chron></span> /PRNewswire/ -- <span value="Australia:CSL" idsrc="xmltag.org" >CSL</span> Seqirus, a business of <span value="Australia:CSL" idsrc="xmltag.org">CSL</span> (ASX: <span value="Australia:CSL" idsrc="xmltag.org">CSL</span>; USOTC: CSLLY), today announced publication of pivotal Phase 3 study results for its MF59^®-adjuvanted http://www.streetinsider.com/PRNewswire/Lancet+Publication+Marks+Important+Advance+in+Influenza+Prevention+for+Older+Adults/27049685.html Thu, 10 Sep 2026 18:40:00 -0400 CSLLY http://www.streetinsider.com/Intl+Ratings/CSL+Ltd.+%28CSL%3AAU%29+%28CSLLY%29+PT+Raised+to+AUD160+at+Citi/26952816.html Citi analyst Laura Sutcliffe raised the price target on CSL Ltd. (CSL:AU) (OTC: CSLLY) to AUD160.00 (from AUD110.00) while maintaining a Neutral rating. http://www.streetinsider.com/Intl+Ratings/CSL+Ltd.+%28CSL%3AAU%29+%28CSLLY%29+PT+Raised+to+AUD160+at+Citi/26952816.html Thu, 20 Aug 2026 07:24:27 -0400 CSLLY http://www.streetinsider.com/Intl+Ratings/CSL+Ltd.+%28CSL%3AAU%29+%28CSLLY%29+PT+Raised+to+AUD160+at+Citi/26952816.html Citi analyst Laura Sutcliffe raised the price target on CSL Ltd. (CSL:AU) (OTC: CSLLY) to AUD160.00 (from AUD110.00) while maintaining a Neutral rating. http://www.streetinsider.com/Intl+Ratings/CSL+Ltd.+%28CSL%3AAU%29+%28CSLLY%29+PT+Raised+to+AUD160+at+Citi/26952816.html Thu, 20 Aug 2026 07:24:27 -0400 CSLLY http://www.streetinsider.com/Analyst+PT+Change/CSL+Ltd.+%28CSL%3AAU%29+%28CSLLY%29+PT+Raised+to+AUD160+at+Citi/26952816.html Citi analyst Laura Sutcliffe raised the price target on CSL Ltd. (CSL:AU) (OTC: CSLLY) to AUD160.00 (from AUD110.00) while maintaining a Neutral rating. http://www.streetinsider.com/Analyst+PT+Change/CSL+Ltd.+%28CSL%3AAU%29+%28CSLLY%29+PT+Raised+to+AUD160+at+Citi/26952816.html Thu, 20 Aug 2026 07:24:27 -0400 CSLLY http://www.streetinsider.com/Analyst+PT+Change/CSL+Ltd.+%28CSL%3AAU%29+%28CSLLY%29+PT+Raised+to+AUD160+at+Citi/26952816.html Citi analyst Laura Sutcliffe raised the price target on CSL Ltd. (CSL:AU) (OTC: CSLLY) to AUD160.00 (from AUD110.00) while maintaining a Neutral rating. http://www.streetinsider.com/Analyst+PT+Change/CSL+Ltd.+%28CSL%3AAU%29+%28CSLLY%29+PT+Raised+to+AUD160+at+Citi/26952816.html Thu, 20 Aug 2026 07:24:27 -0400 CSLLY http://www.streetinsider.com/Intl+Ratings/CSL+Ltd.+%28CSL%3AAU%29+%28CSLLY%29+PT+Raised+to+AUD181+at+UBS/26946314.html UBS analyst David Low raised the price target on CSL Ltd. (CSL:AU) (OTC: CSLLY) to AUD181.00 (from AUD158.00) while maintaining a Buy rating. http://www.streetinsider.com/Intl+Ratings/CSL+Ltd.+%28CSL%3AAU%29+%28CSLLY%29+PT+Raised+to+AUD181+at+UBS/26946314.html Wed, 19 Aug 2026 03:21:33 -0400 CSLLY http://www.streetinsider.com/Intl+Ratings/CSL+Ltd.+%28CSL%3AAU%29+%28CSLLY%29+PT+Raised+to+AUD181+at+UBS/26946314.html UBS analyst David Low raised the price target on CSL Ltd. (CSL:AU) (OTC: CSLLY) to AUD181.00 (from AUD158.00) while maintaining a Buy rating. http://www.streetinsider.com/Intl+Ratings/CSL+Ltd.+%28CSL%3AAU%29+%28CSLLY%29+PT+Raised+to+AUD181+at+UBS/26946314.html Wed, 19 Aug 2026 03:21:33 -0400 CSLLY http://www.streetinsider.com/Analyst+PT+Change/CSL+Ltd.+%28CSL%3AAU%29+%28CSLLY%29+PT+Raised+to+AUD181+at+UBS/26946314.html UBS analyst David Low raised the price target on CSL Ltd. (CSL:AU) (OTC: CSLLY) to AUD181.00 (from AUD158.00) while maintaining a Buy rating. http://www.streetinsider.com/Analyst+PT+Change/CSL+Ltd.+%28CSL%3AAU%29+%28CSLLY%29+PT+Raised+to+AUD181+at+UBS/26946314.html Wed, 19 Aug 2026 03:21:33 -0400 CSLLY http://www.streetinsider.com/Analyst+PT+Change/CSL+Ltd.+%28CSL%3AAU%29+%28CSLLY%29+PT+Raised+to+AUD181+at+UBS/26946314.html UBS analyst David Low raised the price target on CSL Ltd. (CSL:AU) (OTC: CSLLY) to AUD181.00 (from AUD158.00) while maintaining a Buy rating. http://www.streetinsider.com/Analyst+PT+Change/CSL+Ltd.+%28CSL%3AAU%29+%28CSLLY%29+PT+Raised+to+AUD181+at+UBS/26946314.html Wed, 19 Aug 2026 03:21:33 -0400 CSLLY http://www.streetinsider.com/Press+Releases/CSL+Reports+Positive+Top-Line+Phase+3b+Results+Supporting+Planned+Expanded+Pediatric+Filing+for+ANDEMBRY%C2%AE+%28garadacimab-gxii%29+in+Children+with+Hereditary+Angioedema+%28HAE%29/26816978.html <div class="xn-content"> <ul type="disc"><li><span value="Australia:CSL" idsrc="xmltag.org">CSL</span> plans to begin submitting regulatory filings for expanded pediatric indication for ANDEMBRY in the first half of the company's fiscal year</li><li>Full data to be presented at upcoming scientific congress</li></ul><p><span class="legendSpanClass"><location value="LU/us.pa.kinsia" idsrc="xmltag.org" >KING OF PRUSSIA, Pa.</location></span>, <span class="legendSpanClass"><chron>July 27, 2026</chron></span> /PRNewswire/ -- <span>Global biotechnology leader <span value="Australia:CSL" idsrc="xmltag.org">CSL</span> (ASX:CSL; USOTC:CSLLY) today announced positive top-line Phase 3b results evaluating ANDEMBRY^® (garadacimab-gxii) in children aged 2 to 11 years with hereditary angioedema (HAE). ANDEMBRY is </span><span>approved</span> <span>in over 40 countries </span><span>for the prevention of HAE attacks in adult and pediatric patients aged 12 years and older.</span></p> http://www.streetinsider.com/Press+Releases/CSL+Reports+Positive+Top-Line+Phase+3b+Results+Supporting+Planned+Expanded+Pediatric+Filing+for+ANDEMBRY%C2%AE+%28garadacimab-gxii%29+in+Children+with+Hereditary+Angioedema+%28HAE%29/26816978.html Mon, 27 Jul 2026 09:00:00 -0400 A.18406154 A.50201969 CSL CSLLY O.00673957 O.16087478 O.29426449 http://www.streetinsider.com/Press+Releases/CSL+Reports+Positive+Top-Line+Phase+3b+Results+Supporting+Planned+Expanded+Pediatric+Filing+for+ANDEMBRY%C2%AE+%28garadacimab-gxii%29+in+Children+with+Hereditary+Angioedema+%28HAE%29/26816978.html <div class="xn-content"> <ul type="disc"><li><span value="Australia:CSL" idsrc="xmltag.org">CSL</span> plans to begin submitting regulatory filings for expanded pediatric indication for ANDEMBRY in the first half of the company's fiscal year</li><li>Full data to be presented at upcoming scientific congress</li></ul><p><span class="legendSpanClass"><location value="LU/us.pa.kinsia" idsrc="xmltag.org" >KING OF PRUSSIA, Pa.</location></span>, <span class="legendSpanClass"><chron>July 27, 2026</chron></span> /PRNewswire/ -- <span>Global biotechnology leader <span value="Australia:CSL" idsrc="xmltag.org">CSL</span> (ASX:CSL; USOTC:CSLLY) today announced positive top-line Phase 3b results evaluating ANDEMBRY^® (garadacimab-gxii) in children aged 2 to 11 years with hereditary angioedema (HAE). ANDEMBRY is </span><span>approved</span> <span>in over 40 countries </span><span>for the prevention of HAE attacks in adult and pediatric patients aged 12 years and older.</span></p> http://www.streetinsider.com/Press+Releases/CSL+Reports+Positive+Top-Line+Phase+3b+Results+Supporting+Planned+Expanded+Pediatric+Filing+for+ANDEMBRY%C2%AE+%28garadacimab-gxii%29+in+Children+with+Hereditary+Angioedema+%28HAE%29/26816978.html Mon, 27 Jul 2026 09:00:00 -0400 A.18406154 A.50201969 CSL CSLLY O.00673957 O.16087478 O.29426449 http://www.streetinsider.com/Press+Releases/CSL+Reports+Positive+Top-Line+Phase+3b+Results+Supporting+Planned+Expanded+Pediatric+Filing+for+ANDEMBRY%C2%AE+%28garadacimab-gxii%29+in+Children+with+Hereditary+Angioedema+%28HAE%29/26816978.html <div class="xn-content"> <ul type="disc"><li><span value="Australia:CSL" idsrc="xmltag.org">CSL</span> plans to begin submitting regulatory filings for expanded pediatric indication for ANDEMBRY in the first half of the company's fiscal year</li><li>Full data to be presented at upcoming scientific congress</li></ul><p><span class="legendSpanClass"><location value="LU/us.pa.kinsia" idsrc="xmltag.org" >KING OF PRUSSIA, Pa.</location></span>, <span class="legendSpanClass"><chron>July 27, 2026</chron></span> /PRNewswire/ -- <span>Global biotechnology leader <span value="Australia:CSL" idsrc="xmltag.org">CSL</span> (ASX:CSL; USOTC:CSLLY) today announced positive top-line Phase 3b results evaluating ANDEMBRY^® (garadacimab-gxii) in children aged 2 to 11 years with hereditary angioedema (HAE). ANDEMBRY is </span><span>approved</span> <span>in over 40 countries </span><span>for the prevention of HAE attacks in adult and pediatric patients aged 12 years and older.</span></p> http://www.streetinsider.com/Press+Releases/CSL+Reports+Positive+Top-Line+Phase+3b+Results+Supporting+Planned+Expanded+Pediatric+Filing+for+ANDEMBRY%C2%AE+%28garadacimab-gxii%29+in+Children+with+Hereditary+Angioedema+%28HAE%29/26816978.html Mon, 27 Jul 2026 09:00:00 -0400 A.18406154 A.50201969 CSL CSLLY O.00673957 O.16087478 O.29426449 http://www.streetinsider.com/Press+Releases/CSL+Reports+Positive+Top-Line+Phase+3b+Results+Supporting+Planned+Expanded+Pediatric+Filing+for+ANDEMBRY%C2%AE+%28garadacimab-gxii%29+in+Children+with+Hereditary+Angioedema+%28HAE%29/26816978.html <div class="xn-content"> <ul type="disc"><li><span value="Australia:CSL" idsrc="xmltag.org">CSL</span> plans to begin submitting regulatory filings for expanded pediatric indication for ANDEMBRY in the first half of the company's fiscal year</li><li>Full data to be presented at upcoming scientific congress</li></ul><p><span class="legendSpanClass"><location value="LU/us.pa.kinsia" idsrc="xmltag.org" >KING OF PRUSSIA, Pa.</location></span>, <span class="legendSpanClass"><chron>July 27, 2026</chron></span> /PRNewswire/ -- <span>Global biotechnology leader <span value="Australia:CSL" idsrc="xmltag.org">CSL</span> (ASX:CSL; USOTC:CSLLY) today announced positive top-line Phase 3b results evaluating ANDEMBRY^® (garadacimab-gxii) in children aged 2 to 11 years with hereditary angioedema (HAE). ANDEMBRY is </span><span>approved</span> <span>in over 40 countries </span><span>for the prevention of HAE attacks in adult and pediatric patients aged 12 years and older.</span></p> http://www.streetinsider.com/Press+Releases/CSL+Reports+Positive+Top-Line+Phase+3b+Results+Supporting+Planned+Expanded+Pediatric+Filing+for+ANDEMBRY%C2%AE+%28garadacimab-gxii%29+in+Children+with+Hereditary+Angioedema+%28HAE%29/26816978.html Mon, 27 Jul 2026 09:00:00 -0400 A.18406154 A.50201969 CSL CSLLY O.00673957 O.16087478 O.29426449 http://www.streetinsider.com/Press+Releases/CSL+Reports+Positive+Top-Line+Phase+3b+Results+Supporting+Planned+Expanded+Pediatric+Filing+for+ANDEMBRY%C2%AE+%28garadacimab-gxii%29+in+Children+with+Hereditary+Angioedema+%28HAE%29/26816978.html <div class="xn-content"> <ul type="disc"><li><span value="Australia:CSL" idsrc="xmltag.org">CSL</span> plans to begin submitting regulatory filings for expanded pediatric indication for ANDEMBRY in the first half of the company's fiscal year</li><li>Full data to be presented at upcoming scientific congress</li></ul><p><span class="legendSpanClass"><location value="LU/us.pa.kinsia" idsrc="xmltag.org" >KING OF PRUSSIA, Pa.</location></span>, <span class="legendSpanClass"><chron>July 27, 2026</chron></span> /PRNewswire/ -- <span>Global biotechnology leader <span value="Australia:CSL" idsrc="xmltag.org">CSL</span> (ASX:CSL; USOTC:CSLLY) today announced positive top-line Phase 3b results evaluating ANDEMBRY^® (garadacimab-gxii) in children aged 2 to 11 years with hereditary angioedema (HAE). ANDEMBRY is </span><span>approved</span> <span>in over 40 countries </span><span>for the prevention of HAE attacks in adult and pediatric patients aged 12 years and older.</span></p> http://www.streetinsider.com/Press+Releases/CSL+Reports+Positive+Top-Line+Phase+3b+Results+Supporting+Planned+Expanded+Pediatric+Filing+for+ANDEMBRY%C2%AE+%28garadacimab-gxii%29+in+Children+with+Hereditary+Angioedema+%28HAE%29/26816978.html Mon, 27 Jul 2026 09:00:00 -0400 A.18406154 A.50201969 CSL CSLLY O.00673957 O.16087478 O.29426449 http://www.streetinsider.com/Press+Releases/CSL+Reports+Positive+Top-Line+Phase+3b+Results+Supporting+Planned+Expanded+Pediatric+Filing+for+ANDEMBRY%C2%AE+%28garadacimab-gxii%29+in+Children+with+Hereditary+Angioedema+%28HAE%29/26816978.html <div class="xn-content"> <ul type="disc"><li><span value="Australia:CSL" idsrc="xmltag.org">CSL</span> plans to begin submitting regulatory filings for expanded pediatric indication for ANDEMBRY in the first half of the company's fiscal year</li><li>Full data to be presented at upcoming scientific congress</li></ul><p><span class="legendSpanClass"><location value="LU/us.pa.kinsia" idsrc="xmltag.org" >KING OF PRUSSIA, Pa.</location></span>, <span class="legendSpanClass"><chron>July 27, 2026</chron></span> /PRNewswire/ -- <span>Global biotechnology leader <span value="Australia:CSL" idsrc="xmltag.org">CSL</span> (ASX:CSL; USOTC:CSLLY) today announced positive top-line Phase 3b results evaluating ANDEMBRY^® (garadacimab-gxii) in children aged 2 to 11 years with hereditary angioedema (HAE). ANDEMBRY is </span><span>approved</span> <span>in over 40 countries </span><span>for the prevention of HAE attacks in adult and pediatric patients aged 12 years and older.</span></p> http://www.streetinsider.com/Press+Releases/CSL+Reports+Positive+Top-Line+Phase+3b+Results+Supporting+Planned+Expanded+Pediatric+Filing+for+ANDEMBRY%C2%AE+%28garadacimab-gxii%29+in+Children+with+Hereditary+Angioedema+%28HAE%29/26816978.html Mon, 27 Jul 2026 09:00:00 -0400 A.18406154 A.50201969 CSL CSLLY O.00673957 O.16087478 O.29426449 http://www.streetinsider.com/Press+Releases/CSL+Reports+Positive+Top-Line+Phase+3b+Results+Supporting+Planned+Expanded+Pediatric+Filing+for+ANDEMBRY%C2%AE+%28garadacimab-gxii%29+in+Children+with+Hereditary+Angioedema+%28HAE%29/26816978.html <div class="xn-content"> <ul type="disc"><li><span value="Australia:CSL" idsrc="xmltag.org">CSL</span> plans to begin submitting regulatory filings for expanded pediatric indication for ANDEMBRY in the first half of the company's fiscal year</li><li>Full data to be presented at upcoming scientific congress</li></ul><p><span class="legendSpanClass"><location value="LU/us.pa.kinsia" idsrc="xmltag.org" >KING OF PRUSSIA, Pa.</location></span>, <span class="legendSpanClass"><chron>July 27, 2026</chron></span> /PRNewswire/ -- <span>Global biotechnology leader <span value="Australia:CSL" idsrc="xmltag.org">CSL</span> (ASX:CSL; USOTC:CSLLY) today announced positive top-line Phase 3b results evaluating ANDEMBRY^® (garadacimab-gxii) in children aged 2 to 11 years with hereditary angioedema (HAE). ANDEMBRY is </span><span>approved</span> <span>in over 40 countries </span><span>for the prevention of HAE attacks in adult and pediatric patients aged 12 years and older.</span></p> http://www.streetinsider.com/Press+Releases/CSL+Reports+Positive+Top-Line+Phase+3b+Results+Supporting+Planned+Expanded+Pediatric+Filing+for+ANDEMBRY%C2%AE+%28garadacimab-gxii%29+in+Children+with+Hereditary+Angioedema+%28HAE%29/26816978.html Mon, 27 Jul 2026 09:00:00 -0400 A.18406154 A.50201969 CSL CSLLY O.00673957 O.16087478 O.29426449 http://www.streetinsider.com/PRNewswire/CSL+Reports+Positive+Top-Line+Phase+3b+Results+Supporting+Planned+Expanded+Pediatric+Filing+for+ANDEMBRY%C2%AE+%28garadacimab-gxii%29+in+Children+with+Hereditary+Angioedema+%28HAE%29/26816978.html <div class="xn-content"> <ul type="disc"><li><span value="Australia:CSL" idsrc="xmltag.org">CSL</span> plans to begin submitting regulatory filings for expanded pediatric indication for ANDEMBRY in the first half of the company's fiscal year</li><li>Full data to be presented at upcoming scientific congress</li></ul><p><span class="legendSpanClass"><location value="LU/us.pa.kinsia" idsrc="xmltag.org" >KING OF PRUSSIA, Pa.</location></span>, <span class="legendSpanClass"><chron>July 27, 2026</chron></span> /PRNewswire/ -- <span>Global biotechnology leader <span value="Australia:CSL" idsrc="xmltag.org">CSL</span> (ASX:CSL; USOTC:CSLLY) today announced positive top-line Phase 3b results evaluating ANDEMBRY^® (garadacimab-gxii) in children aged 2 to 11 years with hereditary angioedema (HAE). ANDEMBRY is </span><span>approved</span> <span>in over 40 countries </span><span>for the prevention of HAE attacks in adult and pediatric patients aged 12 years and older.</span></p> http://www.streetinsider.com/PRNewswire/CSL+Reports+Positive+Top-Line+Phase+3b+Results+Supporting+Planned+Expanded+Pediatric+Filing+for+ANDEMBRY%C2%AE+%28garadacimab-gxii%29+in+Children+with+Hereditary+Angioedema+%28HAE%29/26816978.html Mon, 27 Jul 2026 09:00:00 -0400 A.18406154 A.50201969 CSL CSLLY O.00673957 O.16087478 O.29426449 http://www.streetinsider.com/PRNewswire/CSL+Reports+Positive+Top-Line+Phase+3b+Results+Supporting+Planned+Expanded+Pediatric+Filing+for+ANDEMBRY%C2%AE+%28garadacimab-gxii%29+in+Children+with+Hereditary+Angioedema+%28HAE%29/26816978.html <div class="xn-content"> <ul type="disc"><li><span value="Australia:CSL" idsrc="xmltag.org">CSL</span> plans to begin submitting regulatory filings for expanded pediatric indication for ANDEMBRY in the first half of the company's fiscal year</li><li>Full data to be presented at upcoming scientific congress</li></ul><p><span class="legendSpanClass"><location value="LU/us.pa.kinsia" idsrc="xmltag.org" >KING OF PRUSSIA, Pa.</location></span>, <span class="legendSpanClass"><chron>July 27, 2026</chron></span> /PRNewswire/ -- <span>Global biotechnology leader <span value="Australia:CSL" idsrc="xmltag.org">CSL</span> (ASX:CSL; USOTC:CSLLY) today announced positive top-line Phase 3b results evaluating ANDEMBRY^® (garadacimab-gxii) in children aged 2 to 11 years with hereditary angioedema (HAE). ANDEMBRY is </span><span>approved</span> <span>in over 40 countries </span><span>for the prevention of HAE attacks in adult and pediatric patients aged 12 years and older.</span></p> http://www.streetinsider.com/PRNewswire/CSL+Reports+Positive+Top-Line+Phase+3b+Results+Supporting+Planned+Expanded+Pediatric+Filing+for+ANDEMBRY%C2%AE+%28garadacimab-gxii%29+in+Children+with+Hereditary+Angioedema+%28HAE%29/26816978.html Mon, 27 Jul 2026 09:00:00 -0400 A.18406154 A.50201969 CSL CSLLY O.00673957 O.16087478 O.29426449 http://www.streetinsider.com/PRNewswire/CSL+Reports+Positive+Top-Line+Phase+3b+Results+Supporting+Planned+Expanded+Pediatric+Filing+for+ANDEMBRY%C2%AE+%28garadacimab-gxii%29+in+Children+with+Hereditary+Angioedema+%28HAE%29/26816978.html <div class="xn-content"> <ul type="disc"><li><span value="Australia:CSL" idsrc="xmltag.org">CSL</span> plans to begin submitting regulatory filings for expanded pediatric indication for ANDEMBRY in the first half of the company's fiscal year</li><li>Full data to be presented at upcoming scientific congress</li></ul><p><span class="legendSpanClass"><location value="LU/us.pa.kinsia" idsrc="xmltag.org" >KING OF PRUSSIA, Pa.</location></span>, <span class="legendSpanClass"><chron>July 27, 2026</chron></span> /PRNewswire/ -- <span>Global biotechnology leader <span value="Australia:CSL" idsrc="xmltag.org">CSL</span> (ASX:CSL; USOTC:CSLLY) today announced positive top-line Phase 3b results evaluating ANDEMBRY^® (garadacimab-gxii) in children aged 2 to 11 years with hereditary angioedema (HAE). ANDEMBRY is </span><span>approved</span> <span>in over 40 countries </span><span>for the prevention of HAE attacks in adult and pediatric patients aged 12 years and older.</span></p> http://www.streetinsider.com/PRNewswire/CSL+Reports+Positive+Top-Line+Phase+3b+Results+Supporting+Planned+Expanded+Pediatric+Filing+for+ANDEMBRY%C2%AE+%28garadacimab-gxii%29+in+Children+with+Hereditary+Angioedema+%28HAE%29/26816978.html Mon, 27 Jul 2026 09:00:00 -0400 A.18406154 A.50201969 CSL CSLLY O.00673957 O.16087478 O.29426449 http://www.streetinsider.com/PRNewswire/CSL+Reports+Positive+Top-Line+Phase+3b+Results+Supporting+Planned+Expanded+Pediatric+Filing+for+ANDEMBRY%C2%AE+%28garadacimab-gxii%29+in+Children+with+Hereditary+Angioedema+%28HAE%29/26816978.html <div class="xn-content"> <ul type="disc"><li><span value="Australia:CSL" idsrc="xmltag.org">CSL</span> plans to begin submitting regulatory filings for expanded pediatric indication for ANDEMBRY in the first half of the company's fiscal year</li><li>Full data to be presented at upcoming scientific congress</li></ul><p><span class="legendSpanClass"><location value="LU/us.pa.kinsia" idsrc="xmltag.org" >KING OF PRUSSIA, Pa.</location></span>, <span class="legendSpanClass"><chron>July 27, 2026</chron></span> /PRNewswire/ -- <span>Global biotechnology leader <span value="Australia:CSL" idsrc="xmltag.org">CSL</span> (ASX:CSL; USOTC:CSLLY) today announced positive top-line Phase 3b results evaluating ANDEMBRY^® (garadacimab-gxii) in children aged 2 to 11 years with hereditary angioedema (HAE). ANDEMBRY is </span><span>approved</span> <span>in over 40 countries </span><span>for the prevention of HAE attacks in adult and pediatric patients aged 12 years and older.</span></p> http://www.streetinsider.com/PRNewswire/CSL+Reports+Positive+Top-Line+Phase+3b+Results+Supporting+Planned+Expanded+Pediatric+Filing+for+ANDEMBRY%C2%AE+%28garadacimab-gxii%29+in+Children+with+Hereditary+Angioedema+%28HAE%29/26816978.html Mon, 27 Jul 2026 09:00:00 -0400 A.18406154 A.50201969 CSL CSLLY O.00673957 O.16087478 O.29426449 http://www.streetinsider.com/PRNewswire/CSL+Reports+Positive+Top-Line+Phase+3b+Results+Supporting+Planned+Expanded+Pediatric+Filing+for+ANDEMBRY%C2%AE+%28garadacimab-gxii%29+in+Children+with+Hereditary+Angioedema+%28HAE%29/26816978.html <div class="xn-content"> <ul type="disc"><li><span value="Australia:CSL" idsrc="xmltag.org">CSL</span> plans to begin submitting regulatory filings for expanded pediatric indication for ANDEMBRY in the first half of the company's fiscal year</li><li>Full data to be presented at upcoming scientific congress</li></ul><p><span class="legendSpanClass"><location value="LU/us.pa.kinsia" idsrc="xmltag.org" >KING OF PRUSSIA, Pa.</location></span>, <span class="legendSpanClass"><chron>July 27, 2026</chron></span> /PRNewswire/ -- <span>Global biotechnology leader <span value="Australia:CSL" idsrc="xmltag.org">CSL</span> (ASX:CSL; USOTC:CSLLY) today announced positive top-line Phase 3b results evaluating ANDEMBRY^® (garadacimab-gxii) in children aged 2 to 11 years with hereditary angioedema (HAE). ANDEMBRY is </span><span>approved</span> <span>in over 40 countries </span><span>for the prevention of HAE attacks in adult and pediatric patients aged 12 years and older.</span></p> http://www.streetinsider.com/PRNewswire/CSL+Reports+Positive+Top-Line+Phase+3b+Results+Supporting+Planned+Expanded+Pediatric+Filing+for+ANDEMBRY%C2%AE+%28garadacimab-gxii%29+in+Children+with+Hereditary+Angioedema+%28HAE%29/26816978.html Mon, 27 Jul 2026 09:00:00 -0400 A.18406154 A.50201969 CSL CSLLY O.00673957 O.16087478 O.29426449 http://www.streetinsider.com/PRNewswire/CSL+Reports+Positive+Top-Line+Phase+3b+Results+Supporting+Planned+Expanded+Pediatric+Filing+for+ANDEMBRY%C2%AE+%28garadacimab-gxii%29+in+Children+with+Hereditary+Angioedema+%28HAE%29/26816978.html <div class="xn-content"> <ul type="disc"><li><span value="Australia:CSL" idsrc="xmltag.org">CSL</span> plans to begin submitting regulatory filings for expanded pediatric indication for ANDEMBRY in the first half of the company's fiscal year</li><li>Full data to be presented at upcoming scientific congress</li></ul><p><span class="legendSpanClass"><location value="LU/us.pa.kinsia" idsrc="xmltag.org" >KING OF PRUSSIA, Pa.</location></span>, <span class="legendSpanClass"><chron>July 27, 2026</chron></span> /PRNewswire/ -- <span>Global biotechnology leader <span value="Australia:CSL" idsrc="xmltag.org">CSL</span> (ASX:CSL; USOTC:CSLLY) today announced positive top-line Phase 3b results evaluating ANDEMBRY^® (garadacimab-gxii) in children aged 2 to 11 years with hereditary angioedema (HAE). ANDEMBRY is </span><span>approved</span> <span>in over 40 countries </span><span>for the prevention of HAE attacks in adult and pediatric patients aged 12 years and older.</span></p> http://www.streetinsider.com/PRNewswire/CSL+Reports+Positive+Top-Line+Phase+3b+Results+Supporting+Planned+Expanded+Pediatric+Filing+for+ANDEMBRY%C2%AE+%28garadacimab-gxii%29+in+Children+with+Hereditary+Angioedema+%28HAE%29/26816978.html Mon, 27 Jul 2026 09:00:00 -0400 A.18406154 A.50201969 CSL CSLLY O.00673957 O.16087478 O.29426449 http://www.streetinsider.com/PRNewswire/CSL+Reports+Positive+Top-Line+Phase+3b+Results+Supporting+Planned+Expanded+Pediatric+Filing+for+ANDEMBRY%C2%AE+%28garadacimab-gxii%29+in+Children+with+Hereditary+Angioedema+%28HAE%29/26816978.html <div class="xn-content"> <ul type="disc"><li><span value="Australia:CSL" idsrc="xmltag.org">CSL</span> plans to begin submitting regulatory filings for expanded pediatric indication for ANDEMBRY in the first half of the company's fiscal year</li><li>Full data to be presented at upcoming scientific congress</li></ul><p><span class="legendSpanClass"><location value="LU/us.pa.kinsia" idsrc="xmltag.org" >KING OF PRUSSIA, Pa.</location></span>, <span class="legendSpanClass"><chron>July 27, 2026</chron></span> /PRNewswire/ -- <span>Global biotechnology leader <span value="Australia:CSL" idsrc="xmltag.org">CSL</span> (ASX:CSL; USOTC:CSLLY) today announced positive top-line Phase 3b results evaluating ANDEMBRY^® (garadacimab-gxii) in children aged 2 to 11 years with hereditary angioedema (HAE). ANDEMBRY is </span><span>approved</span> <span>in over 40 countries </span><span>for the prevention of HAE attacks in adult and pediatric patients aged 12 years and older.</span></p> http://www.streetinsider.com/PRNewswire/CSL+Reports+Positive+Top-Line+Phase+3b+Results+Supporting+Planned+Expanded+Pediatric+Filing+for+ANDEMBRY%C2%AE+%28garadacimab-gxii%29+in+Children+with+Hereditary+Angioedema+%28HAE%29/26816978.html Mon, 27 Jul 2026 09:00:00 -0400 A.18406154 A.50201969 CSL CSLLY O.00673957 O.16087478 O.29426449 http://www.streetinsider.com/FDA/EU+panel+recommends+revoking+Tavneos+marketing+authorization/26695552.html <p>The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended revoking the European Union marketing authorization for TAVNEOS (avacopan), a treatment for adults with severe, active granulomatosis with polyangiitis or microscopic polyangiitis, the main forms of ANCA-associated vasculitis.</p><p>The recommendation, disclosed by Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and CSL (ASX: CSL; USOTC: CSLLY), follows an Article 20 non-pharmacovigilance procedure initiated due to concerns related to data handling in the pivotal Phase 3 ADVOCATE trial, which supported the drug's original approval.</p><p>The CHMP opinion has been forwarded to the European Commission, which is expected to issue a http://www.streetinsider.com/FDA/EU+panel+recommends+revoking+Tavneos+marketing+authorization/26695552.html Fri, 26 Jun 2026 09:02:00 -0400 CSL CSLLY